BCG037 / Biocytogen - LARVOL DELTA

BCG037, a first-in-class anti-human ALPP/ALPG therapeutic ADC that inhibits tumor growth in pancreatic cancer and gastric cancer PDX models (AACR 2026) - "In vivo, BCG037 treatment led to significant and superior tumor growth inhibition in both pancreatic and gastric cancer patient-derived xenograft (PDX) models, outperforming the benchmark ADC, SGN-ALPV-MMAE, and no treatment-related toxicity or weight loss was observed in mice. Collectively, these data validate ALPP/ALPG as promising therapeutic targets and position BCG037 as a highly novel and potent clinical candidate for treating ALPP/ALPG-positive malignancies, including refractory cancers with limited treatment options."

ADC • Gastric Cancer • Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor • ALPP • TOP1